Company Profile

NobleGen Biosciences Inc is building a novel DNA sequencing instrument to enable cost effective personalized medicine, based on highly differentiated IP exclusively licensed from Harvard University and Boston University. Advances in understanding the genomic foundation of disease, along with the increasing availability of targeted therapies, is enabling personalized treatments based on the understanding of molecular changes that contribute to an individual patient's disease. The increasing complexity of the genetic information needed to select those targeted treatments is beginning to exceed the capabilities of existing molecular diagnostic platforms and will require whole genome sequencing. Noblegen Biosciences is building a sequencing platform that aims to meet the requirements to move whole genome sequencing into routine clinical practice. The firm’s ‘Optipore’ DNA sequencing platform is able to take advantage of highly effective nanopore-based DNA separation methods that incorporate high-speed optical detection. Low instrument costs and sub micro-liter sample volumes are possible through custom solid-state nanochips imaged by a simple optical configuration that employs state of the art sCMOS technology, and an off-line chemical DNA conversion process. The Optipore solution enables high accuracy and throughput providing a cost effective solution for whole genome sequencing. Noblegen’s goal is to offer the best cost and performance of any single molecule instrument truly transforming medical prevention, diagnosis and th